Shridar Ganesan, MD, PhD

Shridar Ganesan, MD, PhD, discusses the current limitations and advantages of leveraging circulating-tumor DNA to detect minimal residual disease in patients with cancer, as well as how ctDNA assays may address mechanisms of resistance in clinical practice.

Shridar Ganesan, MD, PhD, discusses improvements in precision medicine and the need to enroll patients with different molecular subtypes into specifically designed clinical trials.